Systematic genomic analysis of SARS-CoV-2 co-infections throughout the pandemic and segregation of the strains involved

Table 3 Clinical characteristics of patients with SARS-CoV-2 co-infections

N: 14
Demographics
Age (median/IQR)	51/45–76
Gender	Total/%
Male	8/57.1
Female	6/42.9
Severity^a/b
Asymptomatic	1/7.1
Mild	8/57.1
Moderate	0/0.0
Severe	4/28.6
Need for healthcare
Emergency	2/14.3
Hospital admission	6/42.9
Hospital admission for COVID-19	3/21.4
ICU	1/7.1
ICU for COVID-19	1/7.1
Previous diseases
None of interest	7/50.0
Heart disease	4/28.6
Oncological	3/21.4
Diabetes	4/28.6
High blood pressure	3/21.4
Overweight/obesity	3/21.4
COPD	1/7.1
Ictus	1/7.1
Autoimmune	1/7.1
Chronic kidney disease	1/7.1
HIV infection	0/0.0
Antiviral treatment^c
Lopinavir/ritonavir	3/21.4
Hydroxychloroquine	2/14.3
Interferon	2/14.3
Dexamethasone	1/7.1
Exitus by COVID-19	3/21.4
Vaccination and serology status^d
Complete vaccination schedule	5/35.7
Incomplete vaccination schedule	0/0.0
Unvaccinated	9/64.3
Previously positive serology for SARS-CoV-2	2/14.3
Previously negative serology for SARS-CoV-2	0/0.0
Serology not available	12/85.7
Risk of overexposure
Healthcare professionals	4/28.6
Involvement in nosocomial outbreak	4/28.6

^aWe have no clinical information on the COVID-19 episode in one patient
^bThe definition of patient severity has been organized according to the following criteria: Mild—general malaise, cough, diarrhoea, headache, fever, anosmia, myalgias, rhinorrhoea; moderate—previous symptoms plus dyspnoea, mild respiratory failure, or unilateral pneumonia; severe—previous symptoms plus bilateral pneumonia or severe respiratory failure
^cPatients with COVID-19 episode who received lopinavir/ritonavir, hydroxychloroquine and interferon were from March and April 2020, when it was considered the standard of care in our centre
^dThe high proportion of unvaccinated patients is largely due to episodes of COVID-19 reported in 2020 and/or early 2021 (7/9), when the vaccine was not yet available

ISSN: 1756-994X